Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare liver diseases
The company aims to address significant unmet medical needs through its pipeline of novel therapeutic candidates, leveraging its expertise in drug discovery and development. Mirum's commitment to advancing patient care is evident in its efforts to deliver effective solutions that improve the quality of life for individuals suffering from conditions related to liver dysfunction. Through rigorous research and clinical studies, Mirum strives to contribute to the advancements in treatments that target these often overlooked diseases.
Discover the top-performing stocks with our analysis. In this video, we dive into the Bollinger Band Squeeze strategy while scanning for opportunities.
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and fatigue were observed.
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target raised to $58. Concerns over age restrictions addressed with proposed new formulation."
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.
